Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894310 | 0.99 | NR1H4 (0.44) | ALOX5CYSLTR2CYSLTR1MAOBMGLL | |
| SCHEMBL9046839 | 0.96 | ALOX5 (0.46) | ALOX5CYSLTR2CYSLTR1MAOBMEN1 | |
| SCHEMBL4472796 | 0.87 | ALOX5 (0.49) | ALOX5MAOBMAOATOP1 | |
| SCHEMBL19339283 | 0.87 | ALOX5 (0.54) | ALOX5MAOBNR4A2MAOAL3MBTL1 | |
| SCHEMBL6762437 | 0.83 | MAOB (0.47) | MAOB | |
| SCHEMBL1581791 | 0.82 | ALOX5 (0.45) | ALOX5MAOBNPC1RAB9AKMT2A | |
| SCHEMBL6899074 | 0.82 | MAOB (0.65) | MAOBMEN1NPC1RAB9AKMT2A | |
| SCHEMBL19243141 | 0.81 | MAOB (0.57) | ALOX5MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6755904 | 0.81 | NR1H4 (0.46) | ALOX5CYSLTR2CYSLTR1MAOBNR4A2 | |
| SCHEMBL6035928 | 0.81 | MAOB (0.49) | ALOX5MAOBMAOAL3MBTL1TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673813-B2 | INHIBITING MEMBRANE TRANSPORT MEDIATED BY THE MULTIDRUG RESISTANCE ASSOCIATED PROTEIN MRP IN A PATIENT BY ADMINISTERING A COMPOUND HAVING AN AMPHIPHILIC ANION AND A MOLECULAR WEIGHT OF FROM 300 TO 950 DALTONS. | JEDLITSCHKY GABRIELE (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20020013370-A1 | Methods for identifying and treating resistant tumors | SAWYER JASON SCOTT (US) | 2002-01-31 | — | — | US | disclosed |
| US-20020010213-A1 | Methods for identifying and treating resistant tumors | SAWYER JASON SCOTT (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1129707-A2 | Methods for identifying and treating resistant tumors | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-09-05 | — | — | EP | disclosed |
| US-6235785-B1 | DRUG RESISTANCE | ELI LILLY AND COMPANY | 2001-05-22 | — | — | US | disclosed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | disclosed |
| EP-0777472-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996036347-A1 | USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5543428-A | ADMINISTERING SUBSTITUTED PHENOXYALKYL COMPOUNDS TO REVERSE DRUG RESISTANCE | ELI LILLY AND COMPANY (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1996006604-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013370-A1 | Methods for identifying and treating resistant tumors | ABCC1, SLC11A2, VHL | ALOX5 2417/4885CYSLTR2 2209/4885CYSLTR1 2385/4885 |
| US-20020010213-A1 | Methods for identifying and treating resistant tumors | ABCC1, SLC11A2, VHL | ALOX5 2417/4885CYSLTR2 2209/4885CYSLTR1 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.